Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.

Hatice Gungor,Azeem Saleem,Syed Babar, Roberto Dina,Mona A El-Bahrawy,Ed Curry,Nona Rama, Michele Chen,Emily Pickford,Roshan Agarwal,Sarah Blagden, Sabin Carme,Cristian Salinas,Sam Madison, Elizabeth Krachey,Ademi Santiago-Walker,Deborah A Smith,Shannon R Morris,Euan A Stronach,Hani Gabra

Journal of nuclear medicine : official publication, Society of Nuclear Medicine（2015）

引用 20|浏览53

暂无评分

摘要

GSK2141795 demonstrated an exposure-response relationship with decreased (18)F-FDG uptake and is active and tolerable. This study's design integrating (18)F-FDG PET, pharmacokinetics, and biomarker analyses demonstrates the potential for clinical development for personalized treatment.

查看译文

关键词

AKT,FDG-PET,GSK2141795,imaging,ovarian cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要